| Project/Area Number |
21591103
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | 財団法人東京都医学総合研究所 (2011)
Tokyo Metropolitan Organization for Medical Research (2009-2010) |
|---|
Principal Investigator |
OKURA Yosio 財団法人東京都医学総合研究所, 認知症・高次脳機能研究分野, 研究員 (10392367)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUMOTO Yoh 財団法人東京都医学総合研究所, 認知症・高次脳機能研究分野, 研究員 (90173921)
KOHYAMA Kuniko 財団法人東京都医学総合研究所, 基盤技術研究センター, 基盤技術研究職員 (80301795)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | アルツハイマー病 / DNAワクチン / Aベータ |
|---|
| Research Abstract |
<Background> It is recently known that in Alzheimer disease, not only Aβoligomers, but also posttranslationally modified Aβspecies and other amyloidogenic peptides are neurotoxic. In the present study, we have attempted to develop a new DNA vaccine targeting these molecules.
<Materials and Methods> Characterization of a newly developed DNA vaccine(Code name, YM3711) was performed in in vitro and in vivo studies. Aβproduction and Aβsecretion abilities were evaluated using YM3711-transfected cultured cells. Anti-Aβand anti-Aβspecies antibody-inducing and Aβ-reducing abilities were determined using plasma and brains from YM3711-vaccinated animals.
<Results> YM3711-transfected cells produced 5-6 fold larger amount of Aβand secreted Aβ3-4 fold higher in the culture supernatant compared with previous DNA vaccines. When vaccinated to mice and rabbits, YM3711 induced not only anti-Aβantibodies, but also antibodies against Aβspecies and amyloidogenic peptides. Importantly, YM3711 vaccination induced reduction of Aβand Aβspecies in model mice.
<Conclusion> Based on the findings, we are currently performing preclinical trials of YM3711.
|
